Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2011;6(7):e22476.
doi: 10.1371/journal.pone.0022476. Epub 2011 Jul 18.

Mortality among patients with cleared hepatitis C virus infection compared to the general population: a Danish nationwide cohort study

Collaborators, Affiliations
Comparative Study

Mortality among patients with cleared hepatitis C virus infection compared to the general population: a Danish nationwide cohort study

Lars Haukali Omland et al. PLoS One. 2011.

Abstract

Background: The increased mortality in HCV-infected individuals partly stems from viral damage to the liver and partly from risk-taking behaviours. We examined mortality in patients who cleared their HCV-infection, comparing it to that of the general population. We also addressed the question whether prognosis differed according to age, substance abuse (alcohol abuse and injection drug use) and comorbidity.

Methodology/principal findings: Patients with cleared HCV-infection were categorized into one of 8 groups according to age (20-39 years or 40-69 years) and patient characteristics (no substance abuse/no comorbidity; substance abuse/no comorbidity; no substance abuse/comorbidity; and substance abuse/comorbidity). For each patient, 4 age- and gender-matched individuals without substance abuse or comorbidity were selected from the general population, comprising a total of 8 comparison cohorts. We analyzed 10-year survival and used stratified Cox Regression analysis to compute mortality rate ratios (MRRs), comparing mortality between the 8 patient groups and the comparison cohorts, adjusting for personal income. Among patients without substance abuse or comorbidity, those aged 40-69 years had the same mortality as the comparison cohort (10-year survival: 95% (95% confidence interval [CI]: 93%-97%), MRR: 1.3 (95% CI: 0.8-2.3)), whereas those aged 20-39 years had higher mortality than the comparison cohort (10-year survival: 93% versus 99%, MRR: 5.7 (95% CI: 2.3-14.0). For both age categories, substance abuse and comorbidity decreased survival and increased MRRs. Patients aged 40-69 years with substance abuse and comorbidity suffered from substantial mortality (MRR: 12.5 (95% CI: 5.1-30.6)).

Conclusions: Mortality in patients aged 40-69 years with cleared HCV-infection is comparable to individuals without HCV, provided they have no substance abuse or comorbidity. Any substance abuse and/or comorbidity not captured in the registries used for our study could explain the increased mortality in patients aged 20-39 years without documented substance abuse or comorbidity.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The author has read the journal's policy and has the following conflicts: Grants received: NO (Roche, Bristol-Meyers Squibb, Merck Sharp & Dohme, GlaxoSmithKline, Abbott, Boehringer Ingelheim, Janssen-Cilag, Swedish-Orphan Drugs). PBC (Roche, Scheering-Plough). Honoria for speaking at meetings: LHO (Tibotec and Merck Sharp & Dohme). All other authors: no conflicts. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.

Figures

Figure 1
Figure 1. Kaplan-Meier survival plot illustrating cumulative survival in patients with cleared HCV-infection and in an age- and gender-matched comparison cohort without comorbidity, alcohol abuse or IDU, according to age at study inclusion.
Solid line: Patients with cleared HCV-infection; broken line: Individuals from the comparison cohort. The left-hand graph illustrates survival among individuals aged 20–39 years at study inclusion. The right-hand graph illustrates survival in those aged 40–69 years at study inclusion.
Figure 2
Figure 2. Kaplan-Meier survival plots illustrating cumulative survival in patients with cleared HCV-infection and in an age- and gender-matched comparison cohort without comorbidity, alcohol abuse or IDU, according to patient characteristics and age at study inclusion.
Solid line: Patients with cleared HCV-infection; broken line: Individuals from the comparison cohort. The left-hand graphs illustrate survival in individuals aged 20–39 years at study inclusion; the right-hand graphs illustrate survival in those aged 40–69 years at inclusion. Top row: Patients with no substance abuse (alcohol abuse or IDU) or comorbidity; second row: patients with substance abuse; third row: patients with comorbidity; and last row: patients with substance abuse and comorbidity.
Figure 3
Figure 3. Cumulative incidence function illustrating cause-specific mortality in patients with cleared HCV-infection and an age- and gender-matched comparison cohort without comorbidity, alcohol abuse or IDU, according to age at study inclusion.
Solid line: Patients with cleared HCV-infection; broken line: Individuals from the comparison cohort. The left-hand graph illustrates survival in individuals aged 20–39 years at study inclusion; the right-hand graph illustrates survival in those aged 40–69 years at inclusion.
Figure 4
Figure 4. Cumulative incidence function illustrating cause-specific mortality in patients with cleared HCV-infection without comorbidity, alcohol abuse or IDU and an age- and gender-matched comparison cohort without comorbidity, alcohol abuse or IDU, according to age at study inclusion.
Solid line: Patients with cleared HCV-infection; broken line: Individuals from the comparison cohort. Left- hand graph illustrates survival in individuals aged 20–39 years at study inclusion; right-hand graph illustrates survival in those aged 40–69 years at inclusion.

Similar articles

Cited by

References

    1. Amin J, Law MG, Bartlett M, Kaldor JM, Dore GJ. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet. 2006;368:938–945. - PubMed
    1. Neal KR, Ramsay S, Thomson BJ, Irving WL. Excess mortality rates in a cohort of patients infected with the hepatitis C virus: a prospective study. Gut. 2007;56:1098–1104. - PMC - PubMed
    1. Omland LH, Jepsen P, Krarup H, Schonning K, Lind B, et al. Increased mortality among persons infected with hepatitis C virus. Clin Gastroenterol Hepatol. 2011;9:71–78. - PubMed
    1. Prasad L, Spicher VM, Negro F, Rickenbach M, Zwahlen M. Little evidence that hepatitis C virus leads to a higher risk of mortality in the absence of cirrhosis and excess alcohol intake: the Swiss Hepatitis C Cohort Study. J Viral Hepat. 2009;16:644–649. - PubMed
    1. Gentile I, Borgia G. Surrogate endpoints and non-inferiority trials in chronic viral hepatitis. J Hepatol. 2010;52:778. - PubMed

Publication types